CD40 Agonistic Monoclonal Antibody APX005M and Chemotherapy ± Nivolumab, for Metastatic Pancreatic Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CD40 Agonistic Monoclonal Antibody APX005M (Sotigalimab) and Chemotherapy, With or Without Nivolumab, for the Treatment of Metastatic Pancreatic Adenocarcinoma: An Open-Label, Multicentre, Phase 1b Study
Lancet Oncol 2021 Jan 01;22(1)118-131, MH O'Hara, EM O'Reilly, G Varadhachary, RA Wolff, ZA Wainberg, AH Ko, G Fisher, O Rahma, JP Lyman, CR Cabanski, R Mick, PF Gherardini, LJ Kitch, J Xu, T Samuel, J Karakunnel, J Fairchild, S Bucktrout, TM LaVallee, C Selinsky, JE Till, EL Carpenter, C Alanio, KT Byrne, RO Chen, OC Trifan, U Dugan, C Horak, VM Hubbard-Lucey, EJ Wherry, R Ibrahim, RH VonderheideFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.